444 related articles for article (PubMed ID: 31287332)
1. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis.
Pinter A; Gerdes S; Papavassilis C; Reinhardt M
J Dermatolog Treat; 2020 Dec; 31(8):769-775. PubMed ID: 31287332
[No Abstract] [Full Text] [Related]
2. Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG; Elewski BE; Lebwohl M; Reich K; Griffiths CE; Papp K; Puig L; Nakagawa H; Spelman L; Sigurgeirsson B; Rivas E; Tsai TF; Wasel N; Tyring S; Salko T; Hampele I; Notter M; Karpov A; Helou S; Papavassilis C; ;
N Engl J Med; 2014 Jul; 371(4):326-38. PubMed ID: 25007392
[TBL] [Abstract][Full Text] [Related]
3. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
Gottlieb AB; Langley RG; Philipp S; Sigurgeirsson B; Blauvelt A; Martin R; Papavassilis C; Mpofu S
J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
5. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients.
Gerdes S; Pinter A; Papavassilis C; Reinhardt M
J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):533-541. PubMed ID: 31599476
[TBL] [Abstract][Full Text] [Related]
6. Continued treatment with secukinumab is associated with high retention or regain of response.
Augustin M; Thaci D; Eyerich K; Pinter A; Radtke M; Lauffer F; Mrowietz U; Gerdes S; Pariser D; Lebwohl M; Sieder C; Melzer N; Reich K
Br J Dermatol; 2020 Jan; 182(1):67-75. PubMed ID: 30972746
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
8. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
Wong IT; Shojania K; Dutz J; Tsao NW
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom.
Warren RB; Halliday A; Graham CN; Gilloteau I; Miles L; McBride D
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2178-2184. PubMed ID: 29846965
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.
Körber A; Papavassilis C; Bhosekar V; Reinhardt M
Drugs Aging; 2018 Feb; 35(2):135-144. PubMed ID: 29404966
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
Ohtsuki M; Morita A; Abe M; Takahashi H; Seko N; Karpov A; Shima T; Papavassilis C; Nakagawa H;
J Dermatol; 2014 Dec; 41(12):1039-46. PubMed ID: 25354738
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
Blauvelt A; Reich K; Mehlis S; Vanaclocha F; Sofen H; Abramovits W; Zhao Y; Gilloteau I; Davenport E; Williams N; Guana A; Tyring S
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1693-1699. PubMed ID: 28602039
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
Tausend W; Downing C; Tyring S
J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
[TBL] [Abstract][Full Text] [Related]
14. Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment.
Yeh NL; Hsu CY; Tsai TF; Chiu HY
Clin Drug Investig; 2019 Dec; 39(12):1195-1203. PubMed ID: 31549347
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept.
Strober B; Gottlieb AB; Sherif B; Mollon P; Gilloteau I; McLeod L; Fox T; Mordin M; Gnanasakthy A; Papavassilis C; Lebwohl MG
J Am Acad Dermatol; 2017 Apr; 76(4):655-661. PubMed ID: 28087133
[TBL] [Abstract][Full Text] [Related]
16. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
Krueger JG; Wharton KA; Schlitt T; Suprun M; Torene RI; Jiang X; Wang CQ; Fuentes-Duculan J; Hartmann N; Peters T; Koroleva I; Hillenbrand R; Letzkus M; Yu X; Li Y; Glueck A; Hasselberg A; Flannery B; Suárez-Fariñas M; Hueber W
J Allergy Clin Immunol; 2019 Sep; 144(3):750-763. PubMed ID: 31129129
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.
Reich K; Blauvelt A; Armstrong A; Langley RG; de Vera A; Kolbinger F; Spindeldreher S; Ren M; Bruin G
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1733-1741. PubMed ID: 31009130
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab: a review in moderate to severe plaque psoriasis.
Garnock-Jones KP
Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
[TBL] [Abstract][Full Text] [Related]
19. Secukinumab (AIN457) for the treatment of psoriasis.
López-Ferrer A; Vilarrasa E; Puig L
Expert Rev Clin Immunol; 2015; 11(11):1177-88. PubMed ID: 26428036
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
van de Kerkhof PC; Griffiths CE; Reich K; Leonardi CL; Blauvelt A; Tsai TF; Gong Y; Huang J; Papavassilis C; Fox T
J Am Acad Dermatol; 2016 Jul; 75(1):83-98.e4. PubMed ID: 27180926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]